NASDAQ: PREPrenetics Global Ltd Stock
$4.97+0.18 (+3.76%)
Updated Apr 25, 2024
PRE Price
$4.97
Fair Value Price
N/A
Market Cap
$60.21M
52 Week Low
$2.85
52 Week High
$15.90
P/E
-0.89x
P/B
0.29x
P/S
3.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.74M
Earnings
-$62.72M
Gross Margin
40.6%
Operating Margin
-289.72%
Profit Margin
-288.5%
Debt to Equity
0.21
Operating Cash Flow
N/A
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRE Overview
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRE is good value based on its book value relative to its share price (0.29x), compared to the US Diagnostics & Research industry average (4.15x)
P/B vs Industry Valuation
PRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRE due diligence checks available for Premium users.
Be the first to know about important PRE news, forecast changes, insider trades & much more!
PRE News
Valuation
PRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.89x
Industry
38.32x
Market
40.97x
PRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.29x
Industry
4.15x
PRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRE's financial health
Profit margin
Revenue
$5.4M
Net Income
-$19.0M
Profit Margin
-350.9%
PRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$254.2M
Liabilities
$44.0M
Debt to equity
0.21
PRE's short-term assets ($93.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRE's short-term assets ($93.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PRE vs Diagnostic & Research Stocks
Prenetics Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.